Literature DB >> 10498901

hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias.

C Sáez1, M A Japón, F Ramos-Morales, F Romero, D I Segura, M Tortolero, J A Pintor-Toro.   

Abstract

The role of oncogenes in pituitary tumorigenesis remains elusive since few genetic changes have been identified so far in pituitary tumors. Pituitary tumor-transforming gene (pttg) has been recently cloned from rat GH4 pituitary tumor cells. We have previously isolated and characterized hpttg from human thymus. In the present study, we analyse the expression of hpttg mRNA in a series of human pituitary adenomas. We show that hpttg is highly expressed in the majority of pituitary adenomas while only very low levels of mRNA can be detected in normal pituitary gland by Northern blot analysis. hPTTG protein was immunolocalized mainly in the cytoplasm of adenoma cells. Other common extra-cranial malignant tumors were also analysed by immunohistochemistry. Interestingly, strong hPTTG immunoreactivity was detected in most adenocarcinomas of mammary and pulmonary origins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498901     DOI: 10.1038/sj.onc.1202914

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression.

Authors:  Zhen-Zhong Feng; Jia-Wei Chen; Zhao-Rui Yang; Guang-Zhong Lu; Zhao-Gen Cai
Journal:  Med Oncol       Date:  2010-12-22       Impact factor: 3.064

2.  Inhibitory effects of anti-sense PTTG on malignant phenotype of human ovarian carcinoma cell line SK-OV-3.

Authors:  Gang Chen; Jing Li; Fujun Li; Xiao Li; Jianfeng Zhou; Yunping Lu; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

3.  Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors.

Authors:  Mar Mora-Santos; M Cristina Limón-Mortés; Servando Giráldez; Joaquín Herrero-Ruiz; Carmen Sáez; Miguel Á Japón; Maria Tortolero; Francisco Romero
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

4.  Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins.

Authors:  Sudhakar Chintharlapalli; Sabitha Papineni; Syng-Ook Lee; Ping Lei; Un Ho Jin; Steven I Sherman; Libero Santarpia; Stephen Safe
Journal:  Mol Carcinog       Date:  2011-01-25       Impact factor: 4.784

Review 5.  The emerging role of pituitary tumor transforming gene in tumorigenesis.

Authors:  Jacob Tfelt-Hansen; Deepthi Kanuparthi; Naibedya Chattopadhyay
Journal:  Clin Med Res       Date:  2006-06

6.  Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase.

Authors:  F Romero; M C Multon; F Ramos-Morales; A Domínguez ; J A Bernal; J A Pintor-Toro; M Tortolero
Journal:  Nucleic Acids Res       Date:  2001-03-15       Impact factor: 16.971

7.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 8.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  Securin promotes the identification of favourable outcome in invasive breast cancer.

Authors:  K Talvinen; H Karra; S Hurme; M Nykänen; A Nieminen; J Anttinen; T Kuopio; P Kronqvist
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

10.  Gene expression profiling of breast cancers with emphasis of beta-catenin regulation.

Authors:  Mee Sook Roh; Sook Hee Hong; Jin Sook Jeong; Hyuk Chan Kwon; Min Chan Kim; Se Heon Cho; Jin Han Yoon; Tae Ho Hwang
Journal:  J Korean Med Sci       Date:  2004-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.